We explored the effects of magnesium treatment on chest pain in pediatric patients suffering from mitral valve prolapse syndrome. In our study involving 230 young participants, we defined hypomagnesaemia as having a serum magnesium level below 1.5 mg/dl.
After identifying 19 patients with insufficient magnesium levels—representing about 8.2% of the group—we treated them with an oral magnesium chloride supplement for five weeks. We were eager to see whether this would help alleviate symptoms, particularly chest pain.
After the treatment period, we observed that magnesium therapy provided statistically significant relief of chest pain for these patients. However, we did not find substantial improvements in other symptoms like palpitations, fatigue, and dyspnea. This finding is vital, as it indicates that while magnesium may play a role in easing chest pain, its overall benefit to other symptoms remains uncertain.
Overall, our study highlights the relatively low prevalence of magnesium deficiency in pediatric patients with mitral valve prolapse compared to adults. Nevertheless, we concluded that magnesium supplementation could be a beneficial approach to address specific symptoms like chest pain in this population.